Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814771 | 0.79 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL14499144 | 0.78 | RXRA (0.41) | ESR1ESR2SHBG | |
| SCHEMBL4814705 | 0.76 | BCHE (0.33) | — | |
| SCHEMBL4810769 | 0.73 | PDK2 (0.33) | ESR1ESR2 | |
| SCHEMBL4816590 | 0.73 | PDCD1 (0.33) | — | |
| SCHEMBL4815280 | 0.72 | ESR2 (0.37) | ESR1ESR2 | |
| SCHEMBL4818120 | 0.70 | — | — | |
| SCHEMBL4818565 | 0.67 | KDM4E (0.36) | ESR1ESR2 | |
| SCHEMBL16281782 | 0.65 | SHBG (0.39) | SHBG | |
| SCHEMBL15137356 | 0.64 | SHBG (0.38) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | ESR1 3300/4885ESR2 2618/4885SLC5A1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.